Previous 10 | Next 10 |
Beaten down biopharma Lexicon Pharmaceuticals ( LXRX +13.7% ) perks up on increased volume, bucking the broad market's sour mood. More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Lexicon Pharmaceuticals ( LXRX ) management reported earnings for the second quarter on July 31 and provided a little more context and detail about the situation with Sanofi ( SNY ) regarding the latter’s attempt to exit the development and marketing collaboration for SGLT-1/2 drug ...
Lexicon Pharmaceuticals, Inc. ( LXRX ) has been badly pummeled this week. It has dropped from last week's close of $5.69 to $1.35 on Wednesday after Sanofi ( SNY ) terminated its collaboration with it to develop, manufacture and commercialize Zynquista for diabetes and Q2 results that re...
Lexicon Pharmaceuticals Inc. (LXRX) Q2 2019 Results Conference Call August 1, 2019 09:00 AM ET Company Participants Kimberly Lee - Head of Investor Relations and Corporate Strategy Lonnel Coats - President and Chief Executive Officer Alex Santini - Executive Vice President and Ch...
Gainers: Big 5 Sporting Goods Corporation (NASDAQ: BGFV ) +35% . Enphase Energy (NASDAQ: ENPH ) +31% . Quad/Graphics (NYSE: QUAD ) +30% . Lattice Semiconductor Corporation (NASDAQ: LSCC ) +22% . Systemax (NYSE: SYX ) +20% . Unisys Corporation (NYSE: UIS ) +21% . Lydall (NYSE: L...
Lexicon Pharmaceuticals ( LXRX ) Q2 results : Revenues: $9.7M (-29.7%); Net product revenue: $8.7M (+19.2%); Collaborative agreements: $0.9M (-85.9%); Royalties and other revenue: $0.2M (+150.0%). More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news, Earnings...
2U (NASDAQ: TWOU ) -41% on Q2 earnings . More news on: 2U, Inc., Sigma Labs, Inc., T2 Biosystems, Inc., Stocks on the move, Read more ...
Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q2 GAAP EPS of -$0.22 misses by $0.16 . Revenue of $9.7M (-29.7% Y/Y) misses by $18.82M . Shares -3.6% PM. Press Release More news on: Lexicon Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
THE WOODLANDS, Texas, July 31, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2019. “We are pleased that recent preliminary results of three Phase 3 clini...
THE WOODLANDS, Texas, July 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has changed the date of its previously announced earnings release, conference call and webcast and will now release financial results for the second quarter of 2...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA ® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related ...
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced its participation in the Bank...
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentati...